With a just-begun phase III trial, Malvern, Pa.-based Galera Therapeutics Inc. is testing its small-molecule mimicker of superoxide dismutase, avasopasem manganese (GC-4419), against severe oral mucositis (SOM) in patients with head and neck cancer.